Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat maintenance after allogeneic HSCT for high-risk AML or MDS
NL-OMON55887Phase 3Active, not recruiting
- Sponsor
- Goethe University Frankfurt
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Panobinostat maintenance with Standard of care (2 arms). Primary endpoint: Overall survival. Started Feb 2019; status: active, not recruiting.
02
Drugs
panobinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON55887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55887.